IVIG (I.V. Immunglobuline)

Privigen®, Intratect®, Octagam® (IVIG)
CSL Behring AG, Biotest AG, Octapharma AG
Human plasma protein with a minimum content of 98 % immunoglobulin IgG
Off-label at: - SJS (Stevens-Johnson Syndrome) - TEN (Toxic Epidermal Necrolysis) - Systemic Lupus erythematosus - Pemphigus vulgaris - Pemphigus foliaceus - Bullous Pemphigoid - Pemphigoid gestationis - Scarring pemphigoid - Epidermolysis bullosa acquisita (EBA) - Linear IgA dermatosis - Dermatomyositis - Scleromyxedema - Kawasaki's syndrome
No
No dermatological disease in the list of specialties
Infusion solution
BB-Diff, liver and kidney values, exclusion HBV, HCV
Blood count, CRP, transaminases, creatinine, β-HCG
Note under Infusion: Vital signs before infusion, every 15 minutes in the first hour and every 30 minutes in the following hours
Note under Infusion: Vital signs before infusion, every 15 minutes in the first hour and every 30 minutes in the following hours
i.v.
2.0 g/kg bw/day spread over 2-5 days. SJS/TEN: IVIG 1g/kgbw/day on 3 days.
Days to weeks
SJS/TEN for 3 days. Dermatomyositis: initial treatment duration 6 months, therapy cycles: every 4 weeks, if no treatment success after 6 cycles, therapy discontinuation. autoimmune bullous dermatoses: average treatment duration: 3-6 months, therapy cycles: every 4 weeks, if course is good: 6 weeks, if no treatment success after 6 cycles, therapy discontinuation. Ka- wasaki syndrome: like autoimmune bullous dermatoses. Scleromyxedema: like autoimmune bullous dermatoses.
10g/100 mL CHF 797.05
Not recommended during treatment cycle
If no effect after typically 20 weeks: STOP
None known
Absolute contraindications: pregnancy, lactation, active infections (sepsis, tuberculosis, severe opportunistic infections)
upper respiratory tract infections, tinea infection, nausea, diarrhea, elevated liver enzymes, oropharyngeal pain
No data
No data
No data
IVIG may affect the effect of live vaccines for a period of 6 weeks to 3 months.
No increased risk